MA28566B1 - PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES - Google Patents

PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES

Info

Publication number
MA28566B1
MA28566B1 MA29430A MA29430A MA28566B1 MA 28566 B1 MA28566 B1 MA 28566B1 MA 29430 A MA29430 A MA 29430A MA 29430 A MA29430 A MA 29430A MA 28566 B1 MA28566 B1 MA 28566B1
Authority
MA
Morocco
Prior art keywords
prostaglandin
treatment
receptor antagonists
inflammatory diseases
antagonists
Prior art date
Application number
MA29430A
Other languages
French (fr)
Inventor
Shomir Ghosh
Amy M Elder
Kenneth G Carson
Kevin T Sprott
Sean J Harrison
Frederick A Hicks
Christelle C Renou
Dominic Reynolds
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA28566B1 publication Critical patent/MA28566B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
MA29430A 2004-04-07 2006-11-02 PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES MA28566B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56041004P 2004-04-07 2004-04-07

Publications (1)

Publication Number Publication Date
MA28566B1 true MA28566B1 (en) 2007-05-02

Family

ID=34965223

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29430A MA28566B1 (en) 2004-04-07 2006-11-02 PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES

Country Status (21)

Country Link
EP (1) EP1740547A1 (en)
JP (1) JP2007532555A (en)
KR (1) KR20070002085A (en)
CN (1) CN101018770A (en)
AR (1) AR048528A1 (en)
AU (1) AU2005233125A1 (en)
BR (1) BRPI0509668A (en)
CA (1) CA2561564A1 (en)
CL (1) CL2008000069A1 (en)
CR (1) CR8659A (en)
EC (1) ECSP066977A (en)
IL (1) IL178328A0 (en)
MA (1) MA28566B1 (en)
MX (1) MXPA06011540A (en)
NO (1) NO20065107L (en)
RU (1) RU2006138603A (en)
TN (1) TNSN06320A1 (en)
TW (1) TW200538127A (en)
UA (1) UA84749C2 (en)
WO (1) WO2005100321A1 (en)
ZA (1) ZA200608955B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0608553A2 (en) 2005-02-24 2010-01-12 Millennium Pharm Inc pgd2 receptor antagonists for the treatment of inflammatory diseases
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
CA2616937A1 (en) 2005-07-29 2007-02-08 F. Hoffman-La Roche Ag Indol-3-yl-carbonyl-piperidin and piperazin derivatives
US9254293B2 (en) 2006-06-16 2016-02-09 The Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH
EP2086970B1 (en) 2006-08-24 2014-02-26 Novartis AG 2-(pyrazin-2-yl)-thiazole and 2-(1h pyrazol-3-yl)-thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders
JPWO2008029924A1 (en) 2006-09-08 2010-01-21 大日本住友製薬株式会社 Cyclic aminoalkylcarboxamide derivatives
RU2009114857A (en) 2006-09-22 2010-10-27 Новартис АГ (CH) HETEROCYCLIC ORGANIC COMPOUNDS
EA200900820A1 (en) 2006-12-20 2010-02-26 Новартис Аг 2-substituted 5-member heterocycles as stearaoyl-soa-desaturase inhibitors (SSDs)
JP5466507B2 (en) 2007-09-27 2014-04-09 興和株式会社 A prophylactic and / or therapeutic agent for anemia comprising a tetrahydroquinoline compound as an active ingredient
DK2327693T3 (en) 2007-12-14 2012-08-13 Pulmagen Therapeutics Asthma Ltd Indoles and their therapeutic use
JP2011102241A (en) * 2008-03-04 2011-05-26 Dainippon Sumitomo Pharma Co Ltd Novel 1-aminocarbonylpiperidine derivative
EP2328619B1 (en) 2008-08-22 2016-12-07 Baxalta GmbH Polymeric benzyl carbonate-derivatives
JP2011256110A (en) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd Manufacturing method of hexahydropyrroloquinoline
EP2415764A4 (en) 2009-03-31 2012-08-08 Kowa Co Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP2955524A3 (en) 2009-11-05 2016-03-23 GlaxoSmithKline LLC Novel process
BR112013000254A2 (en) 2010-07-05 2016-05-24 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclic derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
WO2012174176A1 (en) 2011-06-17 2012-12-20 Merck Sharp & Dohme Corp. Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
UA112667C2 (en) 2011-12-16 2016-10-10 Атопікс Терапеутікс Лімітед COMBINATION OF CRTH2 ANTAGONIST AND PROTON PUMP INHIBITOR FOR TREATMENT OF EOSINOPHILIC ESOPHAGITIS
CN104011021B (en) 2011-12-21 2016-08-24 埃科特莱茵药品有限公司 Hete rocyclic derivatives and the purposes as prostaglandin D 2 receptor conditioning agent thereof
WO2014006585A1 (en) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
JP2018530995A (en) 2015-07-30 2018-10-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Single nucleotide polymorphism allele of human DP-2 gene for detection of sensitivity to hair growth inhibition by PGD2
JOP20190105A1 (en) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc Magl inhibitors
KR20210003160A (en) 2018-04-18 2021-01-11 콘스텔레이션 파마슈티칼스, 인크. Methyl modifying enzyme modulators, compositions and uses thereof
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN113201316B (en) * 2021-04-25 2022-08-26 西南石油大学 temperature/CO 2 pH multi-responsive emulsifier and emulsion and application thereof
CN116425623B (en) * 2023-04-10 2024-02-13 大连凯飞化学股份有限公司 Method for synthesizing 3,5-dichloro-4-methylbenzoic acid by one-pot method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE298747T1 (en) * 1998-03-31 2005-07-15 Shionogi & Co METHOD FOR PRODUCING 5-HYDROXYBENZO(B)THIOPHEN-3-CARBONIC ACID
CZ20032898A3 (en) * 2001-04-30 2004-07-14 Pfizer Products Inc. Process for preparing CETP inhibitors
JP2003321471A (en) * 2002-04-30 2003-11-11 Fuji Photo Film Co Ltd Lactam compound and method of production for the same
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
EP1556047A4 (en) * 2002-10-04 2009-09-30 Millennium Pharm Inc Pgd2 receptor antagonists for the treatment of inflammatory diseases
ES2263015T3 (en) * 2002-10-21 2006-12-01 Warner-Lambert Company Llc TETRAHYDROQUINOLINE DERIVATIVES AS AN ANTHOGONIST OF CRTH2
WO2004052863A1 (en) * 2002-12-06 2004-06-24 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory agent
EP1435356A1 (en) * 2003-01-06 2004-07-07 Warner-Lambert Company LLC Quinoline derivatives as CRTH2 antagonists

Also Published As

Publication number Publication date
RU2006138603A (en) 2008-05-20
JP2007532555A (en) 2007-11-15
MXPA06011540A (en) 2007-01-26
KR20070002085A (en) 2007-01-04
ZA200608955B (en) 2009-05-27
TW200538127A (en) 2005-12-01
CN101018770A (en) 2007-08-15
ECSP066977A (en) 2006-12-29
UA84749C2 (en) 2008-11-25
BRPI0509668A (en) 2007-10-09
AR048528A1 (en) 2006-05-03
CR8659A (en) 2007-06-08
EP1740547A1 (en) 2007-01-10
AU2005233125A1 (en) 2005-10-27
WO2005100321A1 (en) 2005-10-27
CL2008000069A1 (en) 2008-05-16
IL178328A0 (en) 2007-02-11
CA2561564A1 (en) 2005-10-27
TNSN06320A1 (en) 2008-02-22
NO20065107L (en) 2006-12-01

Similar Documents

Publication Publication Date Title
MA28566B1 (en) PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES
ZA200707498B (en) PGD2 receptor antagonists for the treatment of inflammatory diseases
PL376156A1 (en) Pgd2 receptor antagonists for the treatment of inflammatory diseases
CY2017039I1 (en) HIGH-AFFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR
MA29071B1 (en) 2, 6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIDIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
FR20C1014I2 (en) TREATMENT OF SLEEP-WAKE CYCLE DISORDERS
FR15C0046I2 (en) DRUGS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
NO20054343D0 (en) Treatment of immunological disorders using agonists of interleukin-21 / interleukin-21 receptor
FR15C0048I2 (en) IL-17 ANTAGONIST ANTIBODIES
MA28871B1 (en) ACCURATE TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS
SMT201700014B (en) THERAPEUTIC AGENTS FOR THE REDUCTION OF LEVELS OF PARATIROIDOUS HORMONE
MA28791B1 (en) PIPERAZINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
DK1729753T3 (en) Use of an NMDA Receptor Antagonist to Treat Tinnitus Induced by Cochlear Excitotoxicity
MA28555B1 (en) SUBSTITUTED MORPHOLINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
DE60309913D1 (en) BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS SUITABLE FOR THE TREATMENT OF NEUROLOGICAL DISEASES
ATE478864T1 (en) HYDANTOINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP1807391A4 (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
BRPI0912362A2 (en) nmda receptor antagonist for the treatment of neuropsychiatric disorders
EP1940800A4 (en) Novel bicyclic sulfonamides for use as glucocorticoid receptor modulators in the treatment of inflammatory diseases
IL182365A0 (en) 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders
HK1098155A1 (en) Nicotinic receptor agonists for the treatment of inflammatory diseases
FR2887141B1 (en) COMPRESSIVE ORTHESIS TRICOTEE OF THE LOWER MEMBER FOR THE TREATMENT OF CHRONIC VENOUS INSUFFICIENCY
ATE465150T1 (en) PIPERAZINYL DERIVATIVES SUITABLE FOR THE TREATMENT OF DISEASES MEDIATED BY THE GPR38 RECEPTOR
IL182424A0 (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
CY2013037I2 (en) ANTAGONIST II RECEPTOR ANTAGONIST FOR THE THERAPEUTIC TREATMENT OF SYSTEMIC DISEASE IN CATS